Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry - PubMed (original) (raw)
Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry
M Haim et al. Circulation. 1999.
Abstract
Background: The association between elevated blood triglyceride levels and subsequent mortality risk in patients with established coronary heart disease (CHD) has been investigated rarely. The aim of the present study was to investigate this association.
Methods and results: We evaluated mortality over a mean follow-up time of 5. 1 years among 9033 male and 2499 female CHD patients who were screened for participation in the Bezafibrate Infarction Prevention (BIP) Study. A stepwise increase in mortality with increasing serum triglyceride levels was observed in patients with desirable or elevated serum total cholesterol levels and in patients with either desirable or abnormally low HDL cholesterol levels. Multivariate adjustment for factors other than HDL cholesterol yielded a slightly increased adjusted mortality risk with a 1-natural-log-unit elevation of triglyceride levels in men (hazard ratio [HR] 1.14, 95% CI 1.00 to 1.30) and women (HR 1.37, 95% CI 1.04 to 1.88). Excess covariate-adjusted risk was noted among patients with elevated total and LDL cholesterol and in women with HDL cholesterol levels >45 mg/dL. After additional adjustment for HDL cholesterol, the risk of mortality with a 1-natural-log-unit elevation of triglycerides declined in men (HR 1.09, 95% CI 0.94 to 1.26) and in women (HR 1.10, 95% CI 0.80 to 1.50). A trend for increased mortality risk remained in patients with elevated total and LDL cholesterol and in women with HDL cholesterol >45 mg/dL.
Conclusions: Elevated triglyceride levels were associated with a small, independent increased mortality risk in CHD patients. This risk may be increased among subgroups of patients with elevated total cholesterol and LDL cholesterol levels.
Similar articles
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry.
Klempfner R, Erez A, Sagit BZ, Goldenberg I, Fisman E, Kopel E, Shlomo N, Israel A, Tenenbaum A. Klempfner R, et al. Circ Cardiovasc Qual Outcomes. 2016 Mar;9(2):100-8. doi: 10.1161/CIRCOUTCOMES.115.002104. Epub 2016 Mar 8. Circ Cardiovasc Qual Outcomes. 2016. PMID: 26957517 Clinical Trial. - Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S. Goldenberg I, et al. Am J Cardiol. 2009 Jan 1;103(1):41-5. doi: 10.1016/j.amjcard.2008.08.033. Epub 2008 Oct 10. Am J Cardiol. 2009. PMID: 19101227 Clinical Trial. - Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study.
Barasch E, Benderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Pelled B, Reisin L, Roguin N, Goldbourt U. Barasch E, et al. J Clin Epidemiol. 1995 Jun;48(6):757-65. doi: 10.1016/0895-4356(94)00191-r. J Clin Epidemiol. 1995. PMID: 7769406 Clinical Trial. - Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG, Paterson JR. Isles CG, et al. QJM. 2000 Sep;93(9):567-74. doi: 10.1093/qjmed/93.9.567. QJM. 2000. PMID: 10984551 Review. - Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.
Rizos E, Mikhailidis DP. Rizos E, et al. Int J Cardiol. 2002 Mar;82(3):199-207; discussion 207-8. doi: 10.1016/s0167-5273(01)00625-8. Int J Cardiol. 2002. PMID: 11911905 Review.
Cited by
- Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor.
Nowak M, Helleboid-Chapman A, Jakel H, Martin G, Duran-Sandoval D, Staels B, Rubin EM, Pennacchio LA, Taskinen MR, Fruchart-Najib J, Fruchart JC. Nowak M, et al. Mol Cell Biol. 2005 Feb;25(4):1537-48. doi: 10.1128/MCB.25.4.1537-1548.2005. Mol Cell Biol. 2005. PMID: 15684402 Free PMC article. - Niacin or ezetimibe for patients with, or at risk of coronary heart disease.
Guthrie R. Guthrie R. Clin Med Insights Cardiol. 2010 Oct 31;4:99-110. doi: 10.4137/CMC.S5970. Clin Med Insights Cardiol. 2010. PMID: 21079754 Free PMC article. - The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis.
Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, Lane MA, Erwin PJ, Berglund L, Elraiyah T, Montori VM. Murad MH, et al. BMC Endocr Disord. 2012 Mar 31;12:2. doi: 10.1186/1472-6823-12-2. BMC Endocr Disord. 2012. PMID: 22463676 Free PMC article. - Prevalence of Dyslipidemia among Korean Adults: Korea National Health and Nutrition Survey 1998-2005.
Lee MH, Kim HC, Ahn SV, Hur NW, Choi DP, Park CG, Suh I. Lee MH, et al. Diabetes Metab J. 2012 Feb;36(1):43-55. doi: 10.4093/dmj.2012.36.1.43. Epub 2012 Feb 17. Diabetes Metab J. 2012. PMID: 22363921 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical